Joel Beatty
Stock Analyst at Baird
(4.52)
# 252
Out of 5,127 analysts
202
Total ratings
49.08%
Success rate
31.07%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $72 → $47 | $23.21 | +102.50% | 5 | Dec 30, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $16 → $14 | $9.17 | +52.67% | 3 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $160.25 | +30.42% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $86.05 | +45.26% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $11.83 | +60.61% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $3.36 | +108.33% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $38.12 | +75.76% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $2.14 | +180.37% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $35.57 | -74.70% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $26.91 | +15.20% | 4 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $24 | $18.68 | +28.48% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $680 | $795.57 | -14.53% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $17.07 | +69.89% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $76.85 | -14.12% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $167.55 | -3.31% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $29.60 | +38.51% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $14.70 | +8.84% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $294.38 | -75.20% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $22.60 | +41.59% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $90.01 | -16.68% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $2.98 | +134.90% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $60.35 | +7.71% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.16 | +20,589.66% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.37 | +228.47% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $18.63 | +34.19% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $21.39 | +30.90% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.53 | +945.75% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.59 | -21.38% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.31 | +3,258.78% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $65.00 | -10.77% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $36.43 | -34.12% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $6.77 | +165.88% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.17 | +89.27% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.95 | +370.59% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $399.40 | -56.18% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $7.34 | +90.74% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $23.15 | +366.52% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $81.54 | -4.34% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $17.00 | +488.24% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.40 | +631.71% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $4.04 | +11,038.61% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.91 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.34 | +104.36% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $0.50 | +242,324.24% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $9.55 | +98.95% | 3 | Nov 10, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72 → $47
Current: $23.21
Upside: +102.50%
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $9.17
Upside: +52.67%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $160.25
Upside: +30.42%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $86.05
Upside: +45.26%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $11.83
Upside: +60.61%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $3.36
Upside: +108.33%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $38.12
Upside: +75.76%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $2.14
Upside: +180.37%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $35.57
Upside: -74.70%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $26.91
Upside: +15.20%
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $18.68
Upside: +28.48%
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $795.57
Upside: -14.53%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $17.07
Upside: +69.89%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $76.85
Upside: -14.12%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $167.55
Upside: -3.31%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $29.60
Upside: +38.51%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $14.70
Upside: +8.84%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $294.38
Upside: -75.20%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $22.60
Upside: +41.59%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $90.01
Upside: -16.68%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $2.98
Upside: +134.90%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $60.35
Upside: +7.71%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.16
Upside: +20,589.66%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.37
Upside: +228.47%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $18.63
Upside: +34.19%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $21.39
Upside: +30.90%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.53
Upside: +945.75%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.59
Upside: -21.38%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.31
Upside: +3,258.78%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $65.00
Upside: -10.77%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $36.43
Upside: -34.12%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $6.77
Upside: +165.88%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.17
Upside: +89.27%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.95
Upside: +370.59%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $399.40
Upside: -56.18%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $7.34
Upside: +90.74%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $23.15
Upside: +366.52%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $81.54
Upside: -4.34%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $17.00
Upside: +488.24%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.40
Upside: +631.71%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $4.04
Upside: +11,038.61%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.91
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.34
Upside: +104.36%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $0.50
Upside: +242,324.24%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $9.55
Upside: +98.95%